Preliminary results suggest that amivantamab antitumor activity is consistent with that of approved MET TKIs in patients with METex14-driven advanced NSCLC.
This trial confirms benefit of adding neoadjuvant nivolumab to chemotherapy in patients with resectable stage IIIA/B NSCLC, with a pCR rate of 36.8% vs 6.9% with neoadjuvant chemotherapy alone and no impediment to definitive surgery.
A post hoc analysis of the phase III ATLANTIS trial showed that objective responses were maintained or improved in patients with relapsed SCLC who completed 10 cycles of lurbinectedin plus doxorubicin and switched to lurbinectedin monotherapy.
Adagrasib monotherapy was associated with clinical activity, intracranial response, and manageable toxicity in patients with previously treated NSCLC harboring a KRASG12C mutation.
Results from the phase II TACTI-002 trial of the LAG-3 fusion protein eftilagimod alpha in combination with pembrolizumab showed promising durable activity in treatment-naïie patients with advanced NSCLC unselected for PD-L1.
Updated results from the phase I CHRYSALIS-2 trial showed durable antitumor activity with amivantamab + lazertinib in patients with EGFR-mutated NSCLC after progression on both osimertinib and chemotherapy.
Manageable safety and promising antitumor activity observed with CLN-081 in patients with previously treated advanced NSCLC harboring EGFR exon 20 insertion mutations.
Atezolizumab plus chemotherapy showed favorable safety and promising clinical activity in patients with advanced nonsquamous NSCLC and untreated brain metastases, with a 2-year OS rate of 27.5%.
Results from a phase I trial showed that patritumab deruxtecan was active in heavily pretreated patients with unresectable locally advanced or metastatic NSCLC without EGFR activating mutations.
In the phase II OPAL trial, first-line osimertinib combined with platinum-based chemotherapy demonstrated a high response rate and manageable safety in patients with EGFR-mutated advanced NSCLC.
The phase III SKYSCRAPER-02 trial showed no additional benefit with tiragolumab added to first-line atezolizumab plus carboplatin/etoposide in ES-SCLC.
In a post hoc analysis of CheckMate 816, pCR or major pathologic response in the primary tumor was associated with improved EFS with neoadjuvant nivolumab + chemotherapy and chemotherapy in resectable NSCLC.
In this small cohort of patients with KRAS G12C–mutant NSCLC and active, untreated CNS metastases, adagrasib shows encouraging clinical activity and safety, yielding objective intracranial responses in a third of patients.